Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury SeaStar Medical's SCD was featured in four Company presentations at the premier nephrology conference CORRECTION: "Importantly, our findings underscore the opportunity for widespread adoption by hospitals to generate cost savings, while also saving lives" DENVER, Oct. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holdi ...